drugset / Trial / NCT04361097

Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease

NCT04361097 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

What the investigators want to achieve with the protocol is to identify the impact of intestinal microbiota transplantation on the progression of chronic kidney disease. Hypothesis: Modification of intestinal microbioma of CKD patients by TMF decrease the progression of CKD Methodological design: Experimental, prospective, double-blind. Inclusion criteria: Being diagnosed with CKD and creatinine clearance less than 60 mL/minute secondary hypertension and/or diabetes and older than 18 years

Timeline

Start
2018-08-07
Primary completion
2019-11-07
Completion
2020-04-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Faecal Microbiota Transplant Unknown — Oral